Skip to main contentSkip to footer

On Wednesday I had the privilege of attending the Medical Technology Association of Australia (MTAA) Women in MedTech Summit, Sydney.

Oona Reardon, Managing Director, Pulse Economics

On Wednesday I had the privilege of attending the Medical Technology Association of Australia (MTAA) Women in MedTech Summit, Sydney. It was powerful, at times confronting and ultimately inspiring.

A few facts that stayed with me:

🟣 Women were largely excluded from clinical trials until 1993, just 30 years ago. In some fields of biomedical research, male animal studies still outnumber female ones by more than 5 to 1 and the bias persists even when a disease predominantly affects women

🟣 The leading causes of death and disability in women are chronic diseases including dementia, heart disease, stroke and osteoporosis. Yet most of what we know about these conditions came from trials conducted predominantly in men. Women over 50 remain among the most neglected groups in health research

🟣 Only 2% of startup founders who receive funding are women, despite women-led companies delivering 2.5x higher returns

The theme of the day:

We cannot fix what we do not measure and we cannot measure what we do not disaggregate. Sex and gender disaggregated data in clinical trials and post-market surveillance is not a nice-to-have. It is the foundation of equitable and effective care. We need trials designed around patients with unmet need, which means including women across the full spectrum of their biology: reproductive years, pregnancy and the post-partum period, perimenopause and menopause.

This matters because oestrogen does not just govern the reproductive system. It shapes cardiovascular function, bone density, neurological health, immune response and metabolic regulation. A perimenopausal woman and a post-partum woman are not the same patient. Designing for one and assuming it applies to the other is a failure of research design with real consequences for health outcomes.

When procedures and research areas primarily affecting women are systematically undervalued on the MBS and in research funding, we entrench inequity at the structural level. If the majority of women's health funding continues to flow toward reproductive health while chronic disease in women over 50 remains underfunded, we will keep producing evidence that does not reflect the population that needs it most.

Collaboration is the only way forward and we need men in this conversation too, not as observers but as genuine partners. The Australian Government's Women's Health Products Working Group is a meaningful step and one worth watching.

I would also love to see a quarterly webinar series keep this community connected between summits. If you were at the summit and want to continue the conversation, I would love to connect.

#WomenInMedTech #MTAA #HealthEquity #WomensHealth #HealthPolicy #PulseEconomics Jasjit Baveja, Ph.D. Cassandra Szoeke, Rozalina Sarkezians, Dr Melina Georgousakis, Susan McKensey, Robyn Norton, Olena Ivanova, MD, PhD, Rebecca White, Jen O'Neill, Michelle Hill, PhD, Tara Croft, Helen Souris, Anabela Correia Anne O'Neill FTSE PSM Kelly Boxall

Read the LinkedIn post

Previous Post
Just returned from the Digital Health Festival in Melbourne and I left with more questions than answers.
Next Post
Exciting news for Australian medtech!